- Home
- DXC vs IMVT Comparison
DXC vs IMVT Comparison
Compare DXC & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXC
- IMVT
- Stock Information
- Founded
- DXC 1959
- IMVT 2018
- Country
- DXC United States
- IMVT United States
- Employees
- DXC N/A
- IMVT N/A
- Industry
- DXC EDP Services
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DXC Technology
- IMVT Health Care
- Exchange
- DXC Nasdaq
- IMVT Nasdaq
- Market Cap
- DXC 3.0B
- IMVT 2.7B
- IPO Year
- DXC N/A
- IMVT N/A
- Fundamental
- Price
- DXC $14.29
- IMVT $16.95
- Analyst Decision
- DXC Hold
- IMVT Buy
- Analyst Count
- DXC 6
- IMVT 10
- Target Price
- DXC $17.00
- IMVT $40.14
- AVG Volume (30 Days)
- DXC 1.8M
- IMVT 1.4M
- Earning Date
- DXC 07-31-2025
- IMVT 08-05-2025
- Dividend Yield
- DXC N/A
- IMVT N/A
- EPS Growth
- DXC 356.52
- IMVT N/A
- EPS
- DXC 2.10
- IMVT N/A
- Revenue
- DXC $12,871,000,000.00
- IMVT N/A
- Revenue This Year
- DXC N/A
- IMVT N/A
- Revenue Next Year
- DXC N/A
- IMVT N/A
- P/E Ratio
- DXC $6.81
- IMVT N/A
- Revenue Growth
- DXC N/A
- IMVT N/A
- 52 Week Low
- DXC $13.44
- IMVT $12.72
- 52 Week High
- DXC $24.83
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- DXC 42.10
- IMVT 48.32
- Support Level
- DXC $14.27
- IMVT $17.48
- Resistance Level
- DXC $14.93
- IMVT $18.89
- Average True Range (ATR)
- DXC 0.46
- IMVT 0.85
- MACD
- DXC -0.03
- IMVT -0.07
- Stochastic Oscillator
- DXC 9.36
- IMVT 43.73
About DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.